Cargando…

S120: MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q

Detalles Bibliográficos
Autores principales:	Riedel, Anna, Wierzbińska, Justyna A., Toprak, Umut H., Touzart, Aurore, Sollier, Etienne, Kelekçi, Simge, Kelly, Katherine, Weichenhan, Dieter, Pejkovska, Anastasija, Goyal, Ashish, Meinen, Charlotte, Schlesner, Matthias, Westermann, Frank, Brors, Benedikt, Bullinger, Lars, Greif, Philipp, Lübbert, Michael, Heidel, Florian, Fischer, Thomas, Gebhard, Claudia, Schlegelberger, Brigitte, Göhring, Gudrun, Behrens, Yvonne, Jahn, Ekaterina, Döhner, Hartmut, Döhner, Konstanze, Delwel, Ruud, Lutsik, Pavlo, Lipka, Daniel B., Plass, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428226/ http://dx.doi.org/10.1097/01.HS9.0000967392.97333.e2

Ejemplares similares

Translocation t(6;7) in AML-M4 cell line GDM-1 results in MNX1 activation through enhancer-hijacking
por: Weichenhan, Dieter, et al.
Publicado: (2023)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
por: Sollier, Etienne, et al.
Publicado: (2023)

PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML
por: Kelekci, Simge, et al.
Publicado: (2023)

P416: DNA METHYLATION-BASED CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA POINTS TOWARDS KDM3B AS A 5Q HAPLOINSUFFICIENCY CANDIDATE
por: Kelly, Katherine, et al.
Publicado: (2023)

TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3’ neo-enhancer
por: Smith, Charlotte, et al.
Publicado: (2023)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
por: Schmutz, Maximilian, et al.
Publicado: (2023)

Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype
por: Feurstein, Simone, et al.
Publicado: (2014)

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
por: Jahn, Ekaterina, et al.
Publicado: (2023)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression
por: Gentle, Ian Edward, et al.
Publicado: (2021)

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers
por: Lueck, Sonja C., et al.
Publicado: (2016)

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair
por: Herzig, Julia K., et al.
Publicado: (2017)

SEURAT: Visual analytics for the integrated analysis of microarray data
por: Gribov, Alexander, et al.
Publicado: (2010)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper
por: Macintyre, Elizabeth, et al.
Publicado: (2020)

The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML
por: Heidel, Florian H., et al.
Publicado: (2013)

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
por: Cocciardi, Sibylle, et al.
Publicado: (2019)

LncRNA MNX1-AS1 promotes progression of intrahepatic cholangiocarcinoma through the MNX1/Hippo axis
por: Li, Fengwei, et al.
Publicado: (2020)

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2013)

Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia
por: Zhai, Yanan, et al.
Publicado: (2022)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy
por: Grishina, Olga, et al.
Publicado: (2015)

Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique
por: Owattanapanich, Weerapat, et al.
Publicado: (2021)

MNX1-AS1 is a functional oncogene that induces EMT and activates the AKT/mTOR pathway and MNX1 in breast cancer
por: Cheng, Yue, et al.
Publicado: (2019)

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
por: Manz, Kirsi, et al.
Publicado: (2023)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2013)

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
por: Meyer, Tatjana, et al.
Publicado: (2019)

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts
por: Greve, Gabriele, et al.
Publicado: (2023)

VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice
por: Gentner, Eva, et al.
Publicado: (2016)

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
por: Stegelmann, Frank, et al.
Publicado: (2023)

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
por: Schlenk, Richard F., et al.
Publicado: (2016)

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia
por: Zajac, Malgorzata, et al.
Publicado: (2017)

Expression, Clinical Significance, and Functional Prediction of MNX1 in Breast Cancer
por: Tian, Tian, et al.
Publicado: (2018)

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2020)

Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2021)

Club cells employ regeneration mechanisms during lung tumorigenesis
por: Chen, Yuanyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ag0mrmrmdjt71ms6t0jdb3or4